Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCL9
REST API REST API
Homo sapiens
BCL9 is differentially expressed in 187 experiments: 86 organism parts: cerebellum, bone marrow, ... (84 more);, 112 disease states: normal, lung adenocarcinoma, ... (110 more);, 64 cell types 270 cell lines 18 compound treatments and 63 other conditions.
Orthologs Bcl9 (Rattus norvegicus)   BCL9 (Bos taurus)   tai (Drosophila melanogaster)   BCL9 (Gallus gallus)   Bcl9 (Mus musculus)   BCL9 (Danio rerio)   bcl9 (Xenopus laevis)   BCL9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, Wnt receptor signaling pathway, nucleus
UniProt Accession O00512
InterPro Term BCL9_beta-catenin-bd_dom
Search EB-eye ENSG00000116128
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-24147, ... (22 experiments)

Factor Value U/D Experiments
HCC1937
2
 E-MTAB-37, E-MTAB-62
MCF-10A
2
 E-TABM-420, E-GEOD-14990
MDA468
2
 E-MEXP-440, E-MTAB-62
HL-60
1
2
 E-GEOD-5258, E-MTAB-37, E-GEOD-24147
C33A
1
 E-MTAB-37
SQ-5
1
 E-MTAB-62
264 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13909, ... (36 experiments)

Factor Value U/D Experiments
epithelial cell
2
 E-MEXP-2034, E-MEXP-1327
CD33+ myeloid
2
 E-TABM-145, E-AFMX-5
ADC
1
 E-GEOD-19188
M2 macrophage
1
 E-GEOD-5099
leydig cell
1
 E-MTAB-25
single positive thymocyte
1
 E-GEOD-1460
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1577, E-TABM-15, E-GEOD-22148, ... (33 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
 E-GEOD-96, E-MTAB-62, E-MEXP-1327
lung adenocarcinoma
1
3
 E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
breast carcinoma
2
 E-TABM-276, E-GEOD-7307
neuroblastoma
2
 E-MTAB-37, E-MTAB-62
uterine fibroid
2
 E-MTAB-62, E-GEOD-7307
control
1
2
 E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
106 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-3720, E-GEOD-5099, E-MEXP-2590, ... (15 experiments)

Factor Value U/D Experiments
none
3
 E-GEOD-2803, E-GEOD-412, E-MEXP-1230
interleukin-4 (Homo sapiens)
1
 E-GEOD-5099
NaOH
1
 E-MEXP-2590
nickel(II) chloride hexahydrate
1
 E-GEOD-6907
no estradiol
1
 E-GEOD-20081
Cxcl12
1
 E-GEOD-7307
12 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
 E-GEOD-19519
thapsigargin
1
 E-GEOD-19519
tunicamycin
1
 E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-21374, E-GEOD-16363, E-GEOD-19665

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482

Genotype
studied in E-GEOD-3494, E-GEOD-2292, E-TABM-601, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-MEXP-1741, ... (6 experiments)

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1648, E-GEOD-19519, E-GEOD-6919, ... (15 experiments)

Infection
studied in E-MEXP-561

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-23984, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Vehicle
studied in E-GEOD-5258

Processing time: 0.568 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM